Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach

Migraine and Headache

Population pharmacokinetic modeling and simulation of fremanezumab in healthy subjects and patients with migraine

Br J Clin Pharmacol.

Fiedler-Kelly JB, Cohen-Barak O, Morris DN, Ludwig E, Rasamoelisolo M, Shen H, Levi M

doi: 10.1111/bcp.14096.

Migraine and Headache

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

BMC Neurol.

Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, Stauffer VL

doi: 10.1186/s12883-018-1193-2.

RECOMMENDED

Migraine and Headache

Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses

★ 2 Recommended by Prof. Dr Christian Kamm, Faculty Member

doi: 10.1111/head.13845.

RECOMMENDED

Migraine and Headache

Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)

Cephalalgia.

Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R, Raskin J, Pearlman EM, Kudrow D

doi: 10.1177/0333102419864132.

Migraine and Headache

An Open-Label Study Evaluating the Pharmacokinetics and Safety of Diclofenac Potassium for Oral Solution for the Acute Treatment of MWA or MWoA in Pediatric Participants

Headache.

McVige JW, Hogan RM, Shanahan CM, Amend DL, Ferger SM

doi: 10.1111/head.13922.

Migraine and Headache

Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine

Cephalalgia.

Brandes JL, Kudrow D, Yeung PP, Sakai F, Aycardi E, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y

doi: 10.1177/0333102419885905.

RECOMMENDED

Migraine and Headache

Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials

Headache.

Silberstein SD, McAllister P, Ning X, Faulhaber N, Lang N, Yeung P, Schiemann J, Aycardi E, Cohen JM, Janka L, Yang R

doi: 10.1111/head.

RECOMMENDED

Migraine and Headache

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study

Neurology.

Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB; COL MIG-301 Study Group

doi: 10.1212/WNL.

Migraine and Headache

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study

Headache

Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, Barash S, Buse DC

doi: 10.1111/head.14196

Related content

Population pharmacokinetic modeling and simulation of fremanezumab in healthy subjects and patients with migraine

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses

Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)

An Open-Label Study Evaluating the Pharmacokinetics and Safety of Diclofenac Potassium for Oral Solution for the Acute Treatment of MWA or MWoA in Pediatric Participants

Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine

Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study